Refine by
Ventricular Assist Device Articles & Analysis
19 news found
Food and Drug Administration (FDA) has granted Breakthrough Device Designation to the AccuCinch® Ventricular Restoration System. ...
Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces new data validating the benefits of the Company’s BVA-100 blood test (BVA) in improving survival for advanced heart failure patients with left ventricular assist device (LVAD). These data were presented at the International Society for ...
From performing the first open-heart surgeries (adult and pediatric) in New Jersey to running one of the highest volume left-ventricular assist device (LVAD) implant programs in the region, Deborah has stood at the forefront of medical innovation, all while never wavering from its founding mission “there is no price on ...
Company to Advance its Next Generation Percutaneous Ventricular Assist Device Los Gatos, Calif., February 28, 2022 – Supira Medical, Inc., a Shifamed portfolio company that is focused on developing a next-generation solution for temporary mechanical circulatory support, announced today the closing of $30M in Series C financing. ...
The first study, titled, “Blood Volume Analysis Phenotypes in Heart Failure Patients with Left Ventricular Assist Device,” showed that wide total blood volume derangements are seen in LVAD patients up to 64 months post LVAD placement. ...
CorWave announced that it successfully completed its first 60-day preclinical study to evaluate its Left Ventricular Assist Device (LVAD). The results were presented at the 46th Annual Conference of the European Society for Artificial Organs (ESAO) in Hannover. ...
ByCorWave
Berlin, September 2021: Berlin Heart today announces the CE mark and first implantation of an innovative outflow cannula for mechanical circulatory support with the paracorporeal pulsatile EXCOR® ventricular assist device. The EXCOR® Graft Cannula* connects the outflow side of the blood pump to the ascending aorta for left ...
He was treated by extracorporeal membrane oxygenation (ECMO) therapy for many days before he received a left ventricular assist device (LVAD) plus aortic valve replacement (AVR) and a temporary right ventricular assist device (RVAD) a week ago. ...
ByCarmat
For many Berlin Heart staff members, providing ventricular assist devices for people who are waiting for a donor heart is more than just a job. ...
CorWave, a French medical device company committed to the fight against heart failure, announced that it has successfully completed the first 90-day preclinical study to evaluate its left ventricular assist device (LVAD) operating synchronously with the native heart without the use of sensors. ...
ByCorWave
CorWave unveiled a groundbreaking study on the performance of its novel implantable left ventricular assist device (LVAD) at the ISHLT annual meeting, a leading event in the scientific community, which brings together the world's leading experts in the treatment of advanced heart and lung disease to improve patient care. ...
ByCorWave
Berlin Heart is pleased to announce that the first patients are enrolled in the "E-MOTION" study: “The use of the EXCOR® Active driving unit for MObilizaTION of pediatric patients with Ventricular Assist Device support”. This observational, international, multi-center study investigates the improved mobility, patient outcome and ...
The Pediatric Heart-Team from the LMU University Hospital Munich was the first to use this device. The specialized pediatric cardiac surgical team led by Prof. Juergen Hoerer (Pediatric Heart Surgeon) implanted this cannula. ...
BioVentrix, Inc., a privately held medical device company focused on treating congestive heart failure (CHF) via Transcatheter Ventricular Restoration (TCVR), today announced that heart failure specialist Jerry Estep, MD, of the Cleveland Clinic has been appointed co-principal investigator of the pivotal ALIVE Trial studying LIVE Therapy using the Revivent TC ...
CorWave, located in Clichy, Île-de-France, is developing an implantable heart pump (Left Ventricular Assist Device, LVAD) based on a breakthrough technology, the wave membrane pump. ...
ByCorWave
While the BTT indication allows for temporary support by the device, this additional DT indication would allow CARMAT to target the patients who are not eligible to heart transplant who would remain under CARMAT’s device support in the longer term. ...
ByCarmat
CorWave announced today that the latest results of its preclinical Left Ventricular Assist Device (LVAD) development program are presented at the 2020 Virtual OnDemand Conference of the American Society for Artificial Organs (ASAIO), in the Top Abstracts session, available on the ASAIO website1. ...
ByCorWave
The funds will be used to advance product development and clinical efforts for the company’s next generation percutaneous ventricular assist device (pVAD). Additionally, the company announced the appointment of seasoned medical device executive, Dr. ...
Yearick joins Endotronix after leading market development and global expansion for HeartWare, an innovator of minimally invasive, miniaturized, left ventricular assist devices (LVADs) that provide mechanical circulatory support for patients with advanced heart failure. ...